Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanara MedTech Inc. (SMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sanara’s recent filings include multiple Form 8-K current reports that furnish press releases and investor materials related to financial results, strategic decisions and leadership changes.
Form 8-K filings referenced by the company cover several key areas. One set of 8-Ks furnishes press releases announcing quarterly financial results, including discussions of net revenue, segment performance and the classification of Tissue Health Plus (THP) as discontinued operations following a strategic realignment. Another 8-K furnishes a press release detailing the decision to discontinue THP operations and reallocate resources to the core surgical business. Additional 8-K disclosures address executive leadership changes, such as the appointment of a new President and Chief Executive Officer and the designation of a principal accounting officer, along with a summary of the CEO’s employment agreement.
Sanara has also filed an 8-K furnishing an investor presentation under Regulation FD, which it intends to use in meetings with investors and analysts. This presentation, provided as an exhibit, summarizes the company’s priorities and strategy for a future fiscal year and is meant to be considered alongside its other SEC filings and public announcements.
On Stock Titan, these filings can be viewed in sequence to understand how Sanara reports its financial condition, strategic realignments, executive transitions and investor communications. The platform surfaces real-time updates from EDGAR and pairs them with AI-powered summaries that explain the context and key points of each filing, helping readers quickly interpret Form 8-K disclosures, attached exhibits and other regulatory documents related to SMTI.
Sanara MedTech Inc. reports on its business for the year ended December 31, 2025 as a medical technology company focused on surgical wound care and bone fusion products sold primarily to U.S. hospitals and surgical centers.
The company discontinued its Tissue Health Plus value-based wound care program in mid-September 2025 after persistent losses and unsuccessful efforts to secure outside investment, and now operates as a single surgical-focused segment with THP reported as discontinued operations.
Key products include CellerateRX Surgical hydrolyzed collagen, BIASURGE surgical irrigation, and ALLOCYTE Plus cellular bone matrix, supported by preclinical, clinical and health-economic studies showing improved wound outcomes and modeled cost savings per high-risk spinal patient.
Sanara highlights differentiated surgical technologies, a U.S. commercial footprint exceeding 4,000 hospitals, an expanding patent portfolio, and 40 field sales representatives, while also outlining extensive regulatory, competitive, cybersecurity, operational and indebtedness risks, including revenue and liquidity covenants under a senior secured term loan.
Sanara MedTech Inc. reported strong 2025 growth with net revenue of $103.1 million, up 19% from 2024, and reaffirmed 2026 revenue guidance of $116–$121 million, implying 13%–17% additional growth. Revenue expansion was led by soft tissue repair products, especially CellerateRX Surgical, and supported by a broader distributor and facility network.
Adjusted EBITDA rose to $17.0 million from $9.1 million, and operating cash flow improved to $6.8 million. Gross margin reached 93% in Q4 2025. However, a strategic realignment and the discontinuation of Tissue Health Plus drove a $26.5 million noncash impairment and a full-year net loss of $37.6 million. Management highlights a focused surgical business, higher R&D investment, and long-term growth ambitions in the surgical market.
Mackey Ashley M reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Controller Ashley M. Mackey received a grant of 2,804 shares of common stock as equity compensation. The shares were awarded at no cash cost and increased her direct holdings to 5,067 shares after the transaction.
According to the filing, the 2,804 granted shares are restricted stock issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. They will vest in three equal installments on March 22, 2027, March 22, 2028 and March 22, 2029, provided she remains employed with the company through each vesting date.
Waldrop Jacob A. reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Operating Officer Jacob A. Waldrop received a grant of 13,956 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this equity award, his direct holdings total 24,755 shares of common stock.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22 of 2027, 2028 and 2029, provided he remains employed by Sanara MedTech through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Taylor Elizabeth B reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. granted its Chief Financial Officer, Elizabeth B. Taylor, 12,687 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost and increase her direct holdings to 17,632 common shares following the transaction.
The restricted stock will vest in three equal installments, with one-third vesting on March 22 of 2027, 2028, and 2029, respectively. Vesting is conditioned on her continued employment with Sanara MedTech through each vesting date, aligning a portion of her compensation with the company’s long-term performance.
Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that Chief Executive Officer Yon Seth D received a grant of 25,430 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, he directly holds 113,398 common shares.
The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, provided he remains employed by the company through each vesting date. This represents compensation rather than an open-market share purchase.
Sanara MedTech Inc. reported a routine equity compensation event for its Chief Executive Officer, Yon Seth D. On the vesting of 2,082 shares of previously granted restricted stock, the company withheld 596 shares of common stock to cover tax obligations, using a per-share value of $18.87. The footnote clarifies that no shares were issued or sold on the market in this transaction. Following the tax-withholding disposition, the CEO directly owns 87,968 shares of Sanara MedTech common stock.
Sanara MedTech Inc. Chief Executive Officer Seth D. Yon filed an amended insider report updating a prior tax-related share withholding. The company withheld 414 shares of common stock at $20.44 per share to cover taxes on the vesting of 1,446 restricted shares, correcting an earlier filing that had shown 491 shares withheld. This was a tax-withholding disposition only, and the filing states that no shares were issued or sold in the transaction. After this adjustment, Yon directly holds 88,564 shares of Sanara MedTech common stock.
Sanara MedTech Inc.’s Chief Executive Officer, Yon Seth D, reported a Form 4 showing a tax-withholding disposition of 491 shares of common stock on March 1, 2026. These shares were withheld by the company to cover tax obligations from the annual vesting of 1,446 previously granted restricted shares, at a reference price of $20.44 per share. The filing notes that no shares were issued or sold in this transaction, and the CEO’s directly held stake after the withholding was 88,487 common shares.
Sanara MedTech Inc. filed a current report to furnish an investor presentation it plans to use with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation, attached as Exhibit 99.1, outlines the company’s priorities, strategy and anticipated revenue for fiscal 2026.
The company notes this information is being furnished under Regulation FD, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.